Lonza and bluebird bio, Inc., Establish a Long-term Commercial Manufacturing Agreement for Lenti-D™ and LentiGlobin™ Drug ProductsCommercial Manufacturing Agreement • June 9th, 2016 • Bluebird Bio, Inc. • Biological products, (no disgnostic substances)
This agreement follows a successful multi-year clinical manufacturing relationship and provides bluebird bio with a path to commercial supply including dedicated production suites within Lonza’s state-of-the-art facility. This facility is currently under construction for the clinical and commercial supply of viral vectors and virally-modified cell therapy products.
